Previous 10 | Next 10 |
With Humira's LOE looming in 2023, AbbVie stands to lose billions of dollars in revenues. Estimating Humira's likely losses to biosimilars in the US in 2023 and onward is more art than science, albeit there are plentiful clues to work with. AbbVie's long-term guidance around its U...
The SPDR Utilities ETF (XLU) is a popular choice for investors seeking exposure to the utility sector for its stable or even boring business and income. A closer look reveals that it is not boring at all. And we will review its past decade to better understand the sector’s fund...
AbbVie’s Humira was the world’s best-selling pharmaceutical product in 2020, but is facing a loss of exclusivity and increasingly intense biosimilars competition. In preparation for Humira’s sales decline, the company has lined up Rinvoq and Skyrizi in its slate. ...
Everyone talks about how attractive ABBV is, but I couldn't find a detailed DCF model on the stock here at SA. I decided to build such a model, taking into account the synergistic effect of the Allergan acquisition. I considered the prospects for each of AbbVie's new products, whi...
AbbVie is unique in the fact they offer investors growth potential, high-yield, and dividend growth. AbbVie is a great long-term investment for patient investors as they have diversified their portfolio through R&D and acquisition. The company's high-yield dividend is backed b...
Dividend stocks can be a great source of passive income, and fortunately, there is no shortage of dividend-paying companies in the stock market. However, finding those whose businesses -- and payouts -- will remain intact through bull and bear markets can be a bit of a challenge. After all,...
ABBV is a leading biotech business and on the cusp of becoming a Dividend King. What are shares worth today? We detail our full valuation model. For further details see: AbbVie: A Stellar Dividend Growth Pharma Stock
AbbVie has two blockbuster drugs poised to lift sales. Rinvoq's indication for atopic dermatitis is a positive catalyst. Stock offers high dividend payout and upside potential in the next few quarters. ABBV stock is a dividend champ. For further details see: 3 Reason...
Zhongchao (ZCMD) is teaming up with AbbVie's (ABBV) subsidiary AbbVie Pharmaceutical Trading (Shanghai) to develop medical education content.Online healthcare educational services company Zhongchao said the partnership will include, but not be limited to, developing m...
After last week's record inflation read-out at 5%, well-respected hedge fund manager PT Jones shared his opinion at a CNBC interview on why it won't be transitory. In this article, I discuss the three main drivers for inflation. The data shows that they remain at unprecedented levels,...
News, Short Squeeze, Breakout and More Instantly...
On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc’s (NYSE:ABB...
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 15.8%. C...
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX), noting that its AVTX-009 is a promising drug candidate and ...